MoonLake Immunotherapeutics (MLTX) Stock
MLTX has an Alpha Score of 28 out of 100 (poor), computed on Nov 8, 2026 from 2 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported MLTX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $65.53M.
What is MLTX's Alpha Score?
How it works →Alpha Score of 28 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own MLTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 3.37M | $65.53M | +41% |
| Citadel Ken Griffin | 1.97M | $38.41M | +49% |
| Point72 Steve Cohen | 1.16M | $22.56M | -15% |
| Renaissance Technologies Jim Simons (founder) | 643K | $12.52M | +132% |
| Millennium Management Israel Englander | 636K | $12.39M | +10% |
| Marshall Wace | 550K | $10.72M | +394% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are MoonLake Immunotherapeutics insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Jul 27, 26 | Reich Kristian | Chief Scientific Officer | SELL | 1.1K | $22K |
| Jul 22, 26 | Reich Kristian | Chief Scientific Officer | SELL | 2.4K | $49K |
| Jul 21, 26 | Reich Kristian | Chief Scientific Officer | SELL | 50.0K | $1.0M |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are MLTX's key statistics?
Key statistics as of Nov 8, 2026
MLTX price chart
Powered by TradingViewWhat does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing next-level therapies for serious inflammatory diseases. The company targets over-expression of interleukins IL-17A and IL-17F, which drive conditions such as psoriasis, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). These chronic diseases significantly impair patients' quality of life, highlighting critical unmet medical needs. MoonLake Immunotherapeutics innovates through its lead candidate, Sonelokimab, a therapy designed to transform outcomes in these areas. The company sponsors innovative global research and ambitious Phase 3 clinical programs for hidradenitis suppurativa and psoriatic arthritis, leveraging unrivaled expertise to elevate treatment standards. Founded by Jorge Santos da Silva, who serves as Chief Executive Officer, MoonLake applies stellar science to address inflammatory diseases where current solutions fall short, positioning it as a key player in advancing biopharmaceutical solutions for dermatological and rheumatological disorders.